An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...